Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $215.00 at HC Wainwright

Neurocrine Biosciences (NASDAQ:NBIX) had its price objective boosted by research analysts at HC Wainwright from $192.00 to $215.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 62.29% from the stock’s current price.

A number of other equities research analysts also recently issued reports on NBIX. UBS Group cut their price objective on shares of Neurocrine Biosciences from $188.00 to $178.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. Mizuho boosted their price objective on shares of Neurocrine Biosciences from $146.00 to $175.00 and gave the company a “neutral” rating in a research report on Friday, December 12th. Royal Bank Of Canada cut their price objective on shares of Neurocrine Biosciences from $180.00 to $177.00 and set an “outperform” rating for the company in a research report on Thursday, February 12th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $175.00 target price (up from $173.00) on shares of Neurocrine Biosciences in a report on Thursday, January 8th. Finally, Stifel Nicolaus upped their target price on shares of Neurocrine Biosciences from $183.00 to $188.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $176.25.

Neurocrine Biosciences Price Performance

Shares of NBIX stock opened at $132.48 on Tuesday. Neurocrine Biosciences has a 1 year low of $84.23 and a 1 year high of $160.18. The firm has a fifty day moving average price of $131.52 and a 200-day moving average price of $139.01. The company has a market cap of $13.30 billion, a price-to-earnings ratio of 28.43, a PEG ratio of 0.69 and a beta of 0.35.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Wednesday, February 11th. The company reported $1.88 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.36 by ($0.48). Neurocrine Biosciences had a net margin of 16.73% and a return on equity of 16.48%. The business had revenue of $805.50 million for the quarter, compared to the consensus estimate of $804.21 million. During the same period in the previous year, the firm earned $1.69 EPS. The company’s revenue was up 28.3% on a year-over-year basis. Equities research analysts expect that Neurocrine Biosciences will post 4.28 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Kyle Gano sold 36,400 shares of the company’s stock in a transaction on Friday, January 16th. The shares were sold at an average price of $132.70, for a total value of $4,830,280.00. Following the completion of the transaction, the chief executive officer owned 140,407 shares of the company’s stock, valued at approximately $18,632,008.90. This represents a 20.59% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 4.80% of the company’s stock.

Institutional Trading of Neurocrine Biosciences

Several hedge funds have recently bought and sold shares of the stock. USA Financial Formulas purchased a new stake in shares of Neurocrine Biosciences in the fourth quarter worth about $25,000. Golden State Wealth Management LLC lifted its position in shares of Neurocrine Biosciences by 120.5% in the third quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock worth $26,000 after buying an additional 100 shares in the last quarter. Eastern Bank purchased a new stake in shares of Neurocrine Biosciences in the third quarter worth about $27,000. DJE Kapital AG purchased a new stake in shares of Neurocrine Biosciences in the fourth quarter worth about $28,000. Finally, Geneos Wealth Management Inc. lifted its position in shares of Neurocrine Biosciences by 143.6% in the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after buying an additional 135 shares in the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

More Neurocrine Biosciences News

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Acquisition expands Neurocrine’s commercial footprint by adding VYKAT XR (first/only FDA treatment for hyperphagia in Prader‑Willi Syndrome) and creates a three‑product commercial portfolio alongside INGREZZA® and CRENESSITY®. This supports long‑term revenue diversification. Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
• Positive Sentiment: Bank of America reiterated a Buy and raised its price target to $199, signaling bullish analyst conviction that the deal meaningfully increases upside despite a near‑term pipeline lull. Neurocrine Biosciences: Vykat XR Acquisition Unlocks Diversified Growth and Upside Potential Despite Near-Term Pipeline Lull
• Positive Sentiment: Needham reaffirmed a Buy with a $185 target, reinforcing that some buy‑side analysts view the acquisition as value‑creating. Needham & Company Reaffirms Buy on Neurocrine
• Neutral Sentiment: Deal mechanics: Neurocrine will pay $53.00 per Soleno share in an all‑cash transaction valued at about $2.9 billion; a conference call was held to discuss terms. These are execution/funding facts investors will monitor. Neurocrine to buy Soleno Therapeutics for $2.9 billion
• Neutral Sentiment: Market validation for the premium: Soleno shares jumped strongly on the deal, highlighting investor appetite for Soleno’s assets and the strategic rationale for Neurocrine. Soleno Therapeutics (SLNO) Soars 32% on $2.9-Billion Merger
• Negative Sentiment: Some analysts remain cautious: BMO kept a Hold and a $140 target, flagging long‑term execution risks for Ingrezza and orphan market rollouts that could offset acquisition benefits. Balanced View on Neurocrine Biosciences: Favorable Soleno Acquisition Prospects Offset by Long-Term Ingrezza and Orphan Market Execution Risks
• Negative Sentiment: Short‑term headwinds: Neurocrine’s stock initially dropped on the announcement (acquirer sell‑off is common after M&A news) as investors digest the $2.9B cash outlay, integration risk and near‑term pipeline cadence. This Pharma Stock Is Surging 40%. Neurocrine Is Buying It in $2.9 Billion Deal.
• Negative Sentiment: M&A call/transcript and analyst commentary highlight execution and integration questions investors should track (commercial roll‑out for VYKAT XR, orphan market uptake, and funding). Neurocrine Biosciences, Inc. (NBIX) M&A Call Transcript

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.